Imexon

N/A

Report date: 2023/05/05 17:38:55
NME

Base Information

Drug NameImexon
Drug Alias Name伊美克ImexonumAmplimexonAOP-990001BM-06002
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionRibonucleotide reductase inhibitors
TargetsRibonucleotide reductase
Therapy Area/IndicationsNeoplasm MetastasisProstatic NeoplasmsCarcinoma, Non-Small-Cell Lung +[14] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAmplimed Corporation
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAmplimed CorporationUniversity Of Rochester
Active IndicationsN/A
Inactive IndicationsNeoplasm MetastasisProstatic NeoplasmsCarcinoma, Non-Small-Cell Lung +[14] 

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG